ABSTRACT
INTRODUCTION: The purpose of this study was to investigate the safety and efficacy of CyberKnife (CK) robotic radiosurgery for treatment of adrenal metastases. METHODS: We performed a retrospective analysis of 23 patients with adrenal metastases who had been treated with CK between October 2006 and December 2015. Fifteen patients received chemotherapy prior to radiosurgery, all patients underwent computer tomography (CT) fluoroscopically guided percutaneous placement of one to three gold fiducials into the adrenal gland. Nineteen patients were selected for single-fraction radiosurgery with a median dose of 22 Gy, four patients were treated in three fractions with a median dose of 13.5 Gy. RESULTS: Median follow-up time was 23.6 months. Four patients (17%) experienced local relapse during the evaluation period with a mean time of 19 months to tumor progression. The actuarial local tumor control rate was 95% after one year and 81% after two years. Three of the four patients with local recurrence were retreated with CK radiosurgery. Dynamic tumor tracking enabled accurate treatment with correlation errors less than 2 mm, despite extensive respiration-induced target motion up to 22 mm. Apart from nausea directly after treatment in five patients, we observed no early or late treatment-related side effects. CONCLUSIONS: Single fraction robotic radiosurgery for adrenal gland metastases is a safe and effective treatment option for patients who are not eligible for surgical resection.
ABSTRACT
OBJECTIVE: To characterize a novel method for field-size quality assurance of a variable approximately circular aperture collimator by means of dose-area product measurements and to validate its practical use over two years of clinical application. METHODS: To assess methodical limitations, we analyze measurement errors due to change in linac output, beam tuning, uncertainty in MU delivery, daily factors, inherent uncertainty of the large-area parallel-plate ionisation chamber, and misalignment of the large-area parallel-plate ionisation chamber relative to the primary beam axis. To establish a baseline for quality assurance, the dose-area product is measured with the large-area parallel-plate ionisation chamber for all 12 clinical iris apertures in relation to the 60 mm fixed reference aperture. To evaluate the long-term stability of the Iris collimation system, deviation from baseline data is assessed monthly and compared to a priori derived tolerance levels. RESULTS: Only chamber misalignment, variation in output, and uncertainty in MU delivery contribute to a combined error that is estimated at 0.2 % of the nominal field size. This is equivalent to a resolution of 0.005 mm for the 5 mm, and 0.012 mm for the 60 mm field. The method offers ease of use, small measurement time commitment, and is independent of most error sources. Over the observed period, the Iris accuray is within the tolerance levels. CONCLUSIONS: The method is an advantageous alternative to film quality assurance with a high reliability, short measurement time, and superior accuracy in field-size determination.
